MARKET

AKCA

Akcea
AKCA
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
41.41
4.392
3.850
1,846,353,471.47
Pfizer launches Phase 2b vupanorsen study in patients with elevated cholesterol level
Pfizer (PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-L) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), says Ionis Pharmaceuticals (IONS) and its subsidiary
Seekingalpha · 11/04/2020 04:40
Akcea's Waylivra OK'd in England for ultra-rare inherited disorder
Akcea Therapeutics (AKCA), majority-owned affiliate of Ionis Pharmaceuticals (IONS) announces that the National Institute for Health and Care Excellence has issued a positive Final Evaluation Document for WAYLIVRA (volanesorsen) for the
Seekingalpha · 09/18/2020 09:46
Akcea's Waylivra secures NICE recommendation for ultra-rare inherited disorder
Akcea Therapeutics (AKCA), majority-owned affiliate of Ionis Pharmaceuticals (IONS) announces that the National Institute for Health and Care Excellence ((NICE)) has issued a positive Final Evaluation Document for WAYLIVRA (volanesorsen) for
Seekingalpha · 09/18/2020 09:46
MERGER ALERT – AKCA, RST, and BLDR: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Mergers of these Companies
NEW YORK, NY / ACCESSWIRE / September 3, 2020 / The following statement is being issued by Levi & Korsinsky, LLP:Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies.
ACCESSWIRE · 09/03/2020 17:00
Ionis up after cardio-renal pipeline update
Ionis Pharmaceuticals ([[IONS]] +1.3%) is slightly ahead of the broad market advance following its update on its cardio-renal franchise. Highlights:Company expects to file at least 10 marketing applications through 2025.Candidates
Seekingalpha · 09/02/2020 17:45
Mid-Afternoon Market Update: Nasdaq Rises Over 100 Points; Regis Shares Drop After Q4 Results
Toward the end of trading Monday, the Dow traded down 0.72% to 28446.24 while the NASDAQ rose 1% to 11,812.92. The S&P also rose, gaining 0.01% to 3,508.25.
Benzinga · 08/31/2020 18:30
Mid-Day Market Update: Akcea Therapeutics Jumps Following Acquisition News; Acasti Pharma Shares Plummet
Midway through trading Monday, the Dow traded down 0.94% to 28385.03 while the NASDAQ rose 0.23% to 11722.14. The S&P also fell, dropping 0.33% to 3,496.73.
Benzinga · 08/31/2020 16:04
Aimmune Therapeutics rallies on Nestle acquiring, Akcea cheers Ionis acquiring 24% remaining stake, ADiTx Therapeutics and Lipocine among major losers
Gainers: Aimmune Therapeutics (AIMT) +172%, Akcea Therapeutics (AKCA) +60%, Pro-Dex (PDEX) +16%, Kindred Biosciences (KIN) +14%, Neuronetics (STIM) +11%.Losers: ADiTx Therapeutics (ADTX) -11%, Lipocine (LPCN) -11%, Orchard Therapeutics (ORTX) -11%, CNS Pharmaceuticals (CNSP) -9%, Anchiano Therapeutics (ANCN) -8%.
Seekingalpha · 08/31/2020 14:58
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AKCA. Analyze the recent business situations of Akcea through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AKCA stock price target is 28.50 with a high estimate of 41.00 and a low estimate of 16.00.
EPS
Institutional Holdings
Institutions: 114
Institutional Holdings: 23.78M
% Owned: 23.41%
Shares Outstanding: 101.62M
TypeInstitutionsShares
Increased
37
1.59M
New
30
-35.70K
Decreased
18
2.41M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.24%
Pharmaceuticals & Medical Research
+0.11%
Key Executives
Chairman/Director
B. Lynne Parshall
Chief Executive Officer/Director
Damien McDevitt
Chief Financial Officer
Michael Price
Chief Operating Officer
Alex Howarth
Chief Human Resource Officer/Senior Vice President
Carla Poulson
Chief Compliance Officer
Tracy Berns
Other
Louis O Dea
General Counsel
Joshua Patterson
Other
William Andrews
Other
Kyle Jenne
Independent Director
Edward Fitzgerald
Independent Director
Christopher Gabrieli
Independent Director
Elaine Hochberg
Independent Director
Joseph Klein
Independent Director
Richard Moscicki
Independent Director
Amber Salzman
Independent Director
Sandford Smith
Independent Director
Michael Yang
Independent Director
Barbara Yanni
No Data

Webull offers kinds of Akcea stock information, including NASDAQ:AKCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AKCA stock methods without spending real money on the virtual paper trading platform.